Clinical trials: Leukemia, B-Cell, Chronic
Hematopoietic/Lymphoid Cancer, Adult Acute Lymphoblastic Leukemia in Remission
Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by CART19
RATIONALE: Placing a tumor antigen chimeric receptor that has been created in the laboratory into patient autologous or donor-derived T cells may make the body build immune response to kill cancer cells.
- Conditions
- Hematopoietic/Lymphoid Cancer, Adult Acute Lymphoblastic Leukemia in Remission, B-cell Adult Acute Lymphoblastic Leukemia, B-cell Chronic Lymphocytic Leukemia
- Trial name
- CART19 (NCT01864889)
- Testing
- anti-CD19-CAR vector-transduced T cells
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Chinese PLA General Hospital
Patients With CLL Relapsing After an Initial Response (CR, PR ≥ 6 Months) Following no More Than Two Prior Treatment Lines; or, Patients With CLL Refractory (SD, PD or CR/PR < 6 Months) Following no More Than Two Prior Treatment Lines
GIMEMA CLL0809 Study (BendOfa)
In the last ten years there have been significant developments in CLL treatment. The advent of fludarabine, rituximab and the association of chemo-immunotherapy have substantially increased overall response rate, CR rate, time to…
- Trial name
- BendOfa (NCT01244451)
- Testing
- Ofatumumab, Bendamustine
- Where
- 32 sites in Italy
- Volunteers
- 49 people
- Sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
The goal of this study is to evaluate nemtabrutinib compared with investigator's choice of ibrutinib or acalabrutinib in participants with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who have not received…
- Trial name
- NCT06136559
- Testing
- Nemtabrutinib, Ibrutinib, Acalabrutinib
- Where
- 206 sites in United States, Australia and 27 more
- Volunteers
- 1,200 people
- Sponsor
- Merck Sharp & Dohme LLC
Leukemia, Lymphoma
Donor Umbilical Cord Blood Transplantation in Treating Patients With Leukemia, Lymphoma, or Nonmalignant Hematologic Disorders
RATIONALE: Umbilical cord blood transplantation may be able to replace immune cells that were destroyed by the chemotherapy or radiation therapy that was used to kill cancer cells.
- Conditions
- Leukemia, Lymphoma, Myelodysplastic Syndromes, Myelodysplastic-Myeloproliferative Diseases
- Trial name
- NCT00055653
- Testing
- anti-thymocyte globulin, filgrastim, busulfan
- Where
- 25 sites in United States
- Sponsor
- Roswell Park Cancer Institute
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
This phase I trial tests zanubrutinib in combination with sonrotoclax for treating underrepresented ethnic and racial minorities with B-cell non-Hodgkin lymphoma that has come back after a period of improvement (relapsed) or that…
- Conditions
- Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue
- Trial name
- NCT06859008
- Testing
- Biopsy, Biospecimen Collection, Bone Marrow Aspiration
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- City of Hope Medical Center
Leukaemia, Lymphoblastic
A Phase II, Open Label, Single Arm, Multicenter Study of Chlorambucil in Japanese Previously Untreated Patients With Chronic Lymphocytic Leukemia
This study is an open-label, single arm, phase II study of chlorambucil in subjects with previously untreated CLL. The primary objective is to evaluate the response to chlorambucil in Japanese subjects with previously untreated…
- Trial name
- NCT01808326
- Testing
- chlorambucil, tablets
- Where
- 6 sites in Japan
- Volunteers
- 5 people
- Sponsor
- GlaxoSmithKline
Lymphoma
Radiation Therapy and Cyclophosphamide Plus Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Hodgkin's Disease or Non-Hodgkin's Lymphoma
RATIONALE: Radiation therapy uses high-energy x-rays to damage cancer cells. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die.
- Trial name
- NCT00004908
- Testing
- cyclophosphamide, peripheral blood stem cell transplantation, radiation therapy
- Where
- United States
- Sponsor
- Northwestern University
Non-Hodgkin Lymphoma, Burkitt's Lymphoma
Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL)
This study evaluates ADCT-402 in participants with Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL). Participants will participate in a dose escalation phase (Part 1) and dose expansion (Part 2).
- Conditions
- Non-Hodgkin Lymphoma, Burkitt's Lymphoma, Chronic Lymphocytic Leukemia, Lymphoma, Large B-Cell, Diffuse
- Trial name
- NCT02669017
- Testing
- ADCT-402
- Where
- 11 sites in United States, Italy and 1 more
- Volunteers
- 183 people
- Sponsor
- ADC Therapeutics S.A.
Leukemia, Myelodysplastic Syndromes
VNP40101M in Treating Patients With Relapsed or Refractory Leukemia or Myelodysplastic Syndrome
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of VNP40101M in treating patients who have relapsed or…
- Conditions
- Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
- Trial name
- NCT00049686
- Testing
- laromustine
- Where
- United States
- Sponsor
- Vion Pharmaceuticals
Purpura, Thrombocytopenic, Idiopathic, Autoimmune Thrombocytopenic Purpura
Eltrombopag for the Treatment of Immune ThrombocytoPenia (ITP) Secondary to Chronic Lymphoproliferative Disorders (LPDs)
With conventional treatments (i.e. iv Ig, steroids) the overall response rate of ITP secondary to LPD is generally lower than in primary ITP, and usually not higher than 50% (95% CI 27-72).
- Conditions
- Purpura, Thrombocytopenic, Idiopathic, Autoimmune Thrombocytopenic Purpura, Autoimmune Thrombocytopenia, Chronic Lymphocytic Leukemia
- Trial name
- NCT01610180
- Testing
- Eltrombopag Olamine
- Where
- Italy
- Volunteers
- 18 people
- Sponsor
- Fondazione Progetto Ematologia
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
A Clinical Trial on the Safety and Efficacy of TQB3909 Tablets in Patients With Recurrent or Refractory Chronic Lymphocytic Leukemia (CLL) /Small Lymphocytic Lymphoma (SLL) .
This is a phase Ib/II clinical trial to evaluate the safety and efficacy of TQB3909 tablets in patients with recurrent or refractory CLL/SLL.
- Trial name
- NCT05959694
- Testing
- TQB3909 tablet
- Where
- 25 sites in China
- Volunteers
- 107 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
B-cell Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia
Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL
This is a single-center, nonrandomized, open-label dose-escalation study followed by dose-expansion of CD19- CD34t metabolically programmed CAR T-cell therapy in adult patients with relapsed or refractory CD19 B-cell non-Hodgkin…
- Trial name
- NCT05702853
- Testing
- Cyclophosphamide injection, Fludarabine Injection, CD19-CD34t metabolically programmed CAR transduced T-cells
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Medical University of South Carolina
Chronic Lymphocytic Leukemia, Stage I Chronic Lymphocytic Leukemia
Vorinostat, Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
This phase I/II trial studies the side effects and best dose of vorinostat when given together with fludarabine phosphate, cyclophosphamide, and rituximab and to see how well they work in treating patients with previously…
- Conditions
- Chronic Lymphocytic Leukemia, Stage I Chronic Lymphocytic Leukemia, Stage I Small Lymphocytic Lymphoma, Stage II Chronic Lymphocytic Leukemia
- Trial name
- NCT00918723
- Testing
- Fludarabine Phosphate, Cyclophosphamide, Rituximab
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- Fred Hutchinson Cancer Center
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Dasatinib With Fludarabine and Rituximab in Relapsed and Refractory CLL and SLL
Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL) are similar diseases of the white blood cells and are typically treated the same way.
- Trial name
- NCT01173679
- Testing
- dasatinib, Rituximab, fludarabine
- Where
- 3 sites in United States
- Volunteers
- 10 people
- Sponsor
- Massachusetts General Hospital
Recurrent Acute Lymphoblastic Leukemia, Recurrent B Acute Lymphoblastic Leukemia
Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies
This phase I trial tests the safety, side effects and best infusion dose of genetically engineered cells called anti-CD19/CD20/CD22 chimeric antigen receptor (CAR) T-cells following a short course of chemotherapy with…
- Conditions
- Recurrent Acute Lymphoblastic Leukemia, Recurrent B Acute Lymphoblastic Leukemia, Recurrent B-Cell Prolymphocytic Leukemia, Recurrent Chronic Lymphocytic Leukemia
- Trial name
- NCT05418088
- Testing
- Anti-CD19/CD20/CD22 CAR T-Cells, Cyclophosphamide, Fludarabine Phosphate
- Where
- 2 sites in United States
- Volunteers
- 54 people
- Sponsor
- Sumithira Vasu
Lymphoma, Non-Hodgkin, Chronic Lymphocytic Leukemia
A Study of JNJ-64264681 and JNJ-67856633 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia
The primary purpose of this study is to determine: the recommended Phase 2 doses (RP2Ds) of JNJ-64264681 and JNJ 67856633 when administered together in participants with B cell non-Hodgkin lymphoma (NHL) and chronic lymphocytic…
- Trial name
- NCT04657224
- Testing
- JNJ-64264681, JNJ-67856633
- Where
- 28 sites in United States, Australia and 10 more
- Volunteers
- 75 people
- Sponsor
- Janssen Research & Development, LLC
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
A Study of Duvelisib and Venetoclax in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Indolent or Aggressive Non-Hodgkin Lymphoma, Who Have Not Previously Received a Bcl-2 or PI3K Inhibitor
This study is designed to assess the safety, pharmacokinetics, drug-drug interactions, and determine the recommended Phase 2 doses of co administered Duvelisib and Venetoclax in participants with relapsed or refractory chronic…
- Conditions
- Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Non-Hodgkin Lymphoma
- Trial name
- NCT02640833
- Testing
- Duvelisib, Venetoclax
- Where
- 10 sites in United States
- Sponsor
- AbbVie
Graft Versus Host Disease, Leukemia
Graft-Versus-Host Disease Prevention in Treating Patients Who Are Undergoing Bone Marrow Transplantation
RATIONALE: Bone marrow transplantation may be able to replace immune cells that were destroyed by chemotherapy used to kill tumor cells. Sometimes the transplanted cells can make an immune response against normal tissues.
- Conditions
- Graft Versus Host Disease, Leukemia, Lymphoma
- Trial name
- NCT00002456
- Testing
- cyclosporine, methotrexate, allogeneic bone marrow transplantation
- Where
- United States
- Sponsor
- Fred Hutchinson Cancer Center
Non-Hodgkin's B-cell Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell
Safety, PD & Efficacy of MT-3724 for the Treatment of Patients With Relapsed or Refractory DLBCL
The purpose of this study is to evaluate the safety and tolerability of MT-3724 in subjects with relapsed or refractory B-Cell NHL or relapsed and refractory CLL (Part 1 only) and relapsed and refractory DLBCL (Part 2 and Part…
- Conditions
- Non-Hodgkin's B-cell Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell, Small Lymphocytic Leukemia, Diffuse Large B Cell Lymphoma
- Trial name
- MT-3724NHL001 (NCT02361346)
- Testing
- MT-3724 Phase 1, MT-3724 Phase 2
- Where
- 41 sites in United States, Belarus and 8 more
- Volunteers
- 38 people
- Sponsor
- Molecular Templates, Inc.
Chronic Lymphocytic Leukemia
Fludarabine With or Without Cyclophosphamide in Treating Patients With Advanced Chronic Lymphocytic Leukemia
RATIONALE: Drugs used in chemotherapy, such as fludarabine and cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00276848
- Testing
- Fludarabine plus Cyclophosphamide, Fludarabine
- Where
- 135 sites in Austria, Germany
- Volunteers
- 375 people
- Sponsor
- German CLL Study Group
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.